KeyBanc raised the firm’s price target on West Pharmaceutical to $440 from $415 and keeps an Overweight rating on the shares. With positive industry demand factors, the firm sees improved visibility. KeyBanc also argues that record pace of 2023 FDA approvals defies investor skepticism and promises 2024 normalcy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WST:
- West Pharmaceutical price target raised to $415 from $385 at KeyBanc
- Jefferies healthcare analysts to hold an analyst/industry conference call
- Early notable gainers among liquid option names on August 8th
- West Pharmaceutical Stock (NYSE:WST) Falls on Mixed Q2 Results
- West Pharmaceutical ups FY23 adjusted EPS view to $7.65-$7.80 from $7.50-$7.65
